DelveInsight has launched a new report on Geographic Atrophy Pipeline
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.
Request for free sample copy- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight
Geographic Atrophy Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of Geographic Atrophy Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.
Geographic Atrophy Pipeline
GA is a progressive, irreversible and blinding disease that tends to affect both eyes. Nearly two-third geographic atrophy cases are reported in the people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK. GA is characterized by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or ‘blind spots’. These dark patches represent the death of different cell types in the retina, including the light-sensitive photoreceptors. A visual acuity test is used to assess GA. Unfortunately; visual acuity alone does not fully capture the functional impact of GA such as loss of reading ability, highlighting the need for improved testing.
Geographic Atrophy Treatment
Currently, there are no approved treatments present for GA. The Age-Related Eye Disease Study (AREDS) study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene and zinc could significantly reduce the risk of progressing to advanced AMD and sometimes low visual aids and counseling is also helpful. Several therapies which reached in advanced stage of development are already failed, however currently several therapies are in the pipeline to prevent the progression of GA. GA market is expected to grow significantly in the upcoming years owing to expected
Geographic Atrophy Drugs
Geographic Atrophy Report Highlights
Request for free sample copy– https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight
Table of content
1. Report Introduction
2. Geographic Atrophy (GA)
3. Geographic Atrophy (GA) Current Treatment Patterns
4. Geographic Atrophy (GA) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Geographic Atrophy (GA) Late Stage Products (Phase-III)
7. Geographic Atrophy (GA) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Geographic Atrophy (GA) Discontinued Products
13. Geographic Atrophy (GA) Product Profiles
14. Geographic Atrophy (GA) Key Companies
15. Geographic Atrophy (GA) Key Products
16. Dormant and Discontinued Products
17. Geographic Atrophy (GA) Unmet Needs
18. Geographic Atrophy (GA) Future Perspectives
19. Geographic Atrophy (GA) Analyst Review
20. Appendix
21. Report Methodology
What are the key questions answered?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/